These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15034836)

  • 1. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.
    Martínez E; Domingo P; Galindo MJ; Milinkovic A; Arroyo JA; Baldovi F; Larrousse M; León A; de Lazzari E; Gatell JM
    Clin Infect Dis; 2004 Apr; 38(7):1017-23. PubMed ID: 15034836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
    Montes ML; Pulido F; Barros C; Condes E; Rubio R; Cepeda C; Dronda F; Antela A; Sanz J; Navas E; Miralles P; Berenguer J; Pérez S; Zapata A; González-García JJ; Peña JM; Vázquez JJ; Arribas JR
    J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.
    De Socio GV; Bonfanti P; Ricci E; Orofino G; Madeddu G; Penco G; Gianelli E; Martinelli C; Carradori S; Quirino T; Rizzardini G;
    Biomed Pharmacother; 2008 Jan; 62(1):16-20. PubMed ID: 17851026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.
    Shafran SD; Mashinter LD; Roberts SE
    HIV Med; 2005 Nov; 6(6):421-5. PubMed ID: 16268824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lopinavir/ritonavir combination and total/HDL cholesterol ratio.
    Valerio L; Fontas E; Pradier C; Lavrut T; Garraffo R; Dunais B; Cua E; Dellamonica P
    J Infect; 2005 Apr; 50(3):229-35. PubMed ID: 15780417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
    Moltó J; Santos JR; Negredo E; Miranda C; Videla S; Clotet B
    J Antimicrob Chemother; 2007 Aug; 60(2):436-9. PubMed ID: 17556354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
    Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
    Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.
    Guest JL; Ruffin C; Tschampa JM; DeSilva KE; Rimland D
    Pharmacotherapy; 2004 Jun; 24(6):727-35. PubMed ID: 15222662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
    J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
    Bongiovanni M; Chiesa E; Monforte Ad; Bini T
    Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.
    Bongiovanni M; Bini T; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Biasi P; Adorni F; Monforte AD
    AIDS Res Hum Retroviruses; 2006 Feb; 22(2):132-8. PubMed ID: 16478394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen.
    Azria E; Moutafoff C; Schmitz T; Le Meaux JP; Krivine A; Pannier E; Firtion G; Compagnucci A; Finkielsztejn L; Taulera O; Tsatsaris V; Cabrol D; Launay O
    Antivir Ther; 2009; 14(3):423-32. PubMed ID: 19474476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
    Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
    Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.